Device Trial Radar · NCT02607527
Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System
Last checked: Nov 20, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
May 8, 2017
Primary completion
Jan 17, 2019
Study completion Dec 19, 2019
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.
Conditions
- Mitral Valve Insufficiency
Interventions
Mitral Valve IRIS RingDevice
Transcatheter implantation of the IRIS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute Safety defined as incidence of adverse eventsTime frame: Procedure through 30 days post procedure
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Dante Pazzanese de Cardiologia
São Paulo, Brazil
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.